Clik here to view.
2013 M&A Of The Year Nominee: McKesson/ Celesio
It's time for the IN VIVO Blog's Sixth Annual Deal of the Year! competition. This year we're once again presenting awards in three categories to highlight the most interesting and creative deal making...
View ArticleClik here to view.
2013 M&A of the Year Nominee: Valeant/B&L
It's time for the IN VIVO Blog's Sixth Annual Deal of the Year! competition. This year we're once again presenting awards in three categories to highlight the most interesting and creative deal making...
View ArticleClik here to view.
And the Nominees for IVB's 2013 Alliance of the Year Are ...
We've nominated five 2013 deals for Alliance of the Year. It's time for you, esteemed readers of The In Vivo Blog, to decide the winner. From medication adherence to geographic diversity to hot new...
View ArticleClik here to view.
And The Nominees for IVB's 2013 Financing of the Year Are ...
We've nominated six 2013 deals for Financing of the Year. It's time for you, esteemed readers of The In Vivo Blog, to decide the winner. From Series A to IPO, from twinkle-in-the-eye science to Phase...
View ArticleClik here to view.
And the Nominees for IVB's 2013 M&A of the Year Are ...
We've nominated five 2013 Deals for M&A of the Year. It's time for you, esteemed readers of The In Vivo Blog, to decide the winner. It's an eclectic bunch this year -- we can't wait to see what...
View ArticleClik here to view.
Three Polls, One Page: Vote for IVBs Deals of the Year
We've set up a single page where you can vote on M&A, Financing, and Alliance of the Year. Polls open til January 7. Good luck to the nominees! VOTE HERE.Copyright © 2014 Informa Business...
View ArticleClik here to view.
2013 Deals Review Finds Spec Pharma, Bolt Ons Dominated M&A
As the door shuts on 2013 and we reflect on the year’s biopharma M&A activity, what’s most noteworthy is the activity of specialty pharmaceutical and big biotech companies, which supplanted Big...
View ArticleClik here to view.
And The Roger Goes To ... Our Deals of the Year Winners!
To Claim Award: Ctrl-P, cut along border, tape to plaque (note: plaque not included).M&A of the Year: Amgen/OnyxCongratulations to Amgen and Onyx, who've won, with more than 62% of the vote, our...
View ArticleClik here to view.
A Rush And A Push And The Financings Of The Fortnight Is Ours
Meet us at the St. Francis, and bring your own damn water!Happy Morgan's Eve, everyone. If you’re like FOTF, you’ve been preparing for the week ahead by breaking your day into 25-minute conversations....
View ArticleClik here to view.
JPM Survival Guide: DOTW Keeps the Party Going
The last few years have been quite a bash for biotech. Astoundingly, the NASDAQ Biotechnology Index (NBI) has added more now than it did during the genomics bubble.Since the current biotech rally...
View ArticleClik here to view.
Return to Seller: GlycoFi Next Tech to Exit Merck?
As the J.P. Morgan conference began to clog the San Francisco streets and restaurants on Sunday night, Alnylam Pharmaceuticals got the party started with a bang. In industry's first major deal of the...
View ArticleClik here to view.
Deals Of The Week: New Remedies Sought From Nature And Old Technologies
To help calm many a frazzled J. P. Morgan attendee trying to get to grips with new ideas, technologies and market entrants announced each year at that key U.S. conference, there’s nothing like a return...
View ArticleClik here to view.
Financings Of The Fortnight Asks For The Envelope, Please...
"And the Best Hair Restoration Product of 2013 goes to..."It's awards season, as they say in Hollywood, and this blog is no stranger to polished hardware. A bit later, we’ve got another red-carpeted...
View ArticleClik here to view.
Deals Of The Week: New Academia/Industry Partnership Template In Eisai/JHU...
As founder and president of a coalition working to enhance academic drug-discovery and collaborations between academia and industry, Barbara Slusher has a good idea of the advantages and pitfalls of...
View ArticleClik here to view.
Deals Of The Week Looks at The Intersection Of Patient Empowerment, Generic...
It’s a challenge to pick up an annual report or listen to a CEO present at a conference these days without reading or hearing something about “patients being at the center of everything we do.” But...
View ArticleClik here to view.
These Days, You Can't Spell Financings Of The Fortnight Without "I-P-O"
It turns out a lot of the words that contain the letters "IPO" are biomedical words: Pluripotent. Liposomal. Adiposis. Gallipot. And it turns out a lot of biomedical companies have IPO in them, too....
View ArticleClik here to view.
Can Novel-Novel Combinations Work? Deals Of The Week Watches Merck Test The...
Merck & Co. Inc.’s Feb. 5 announcement that it is collaborating with three companies to test various combinations of its investigational oncology compound MK-3475 with their drugs highlights the...
View ArticleClik here to view.
Deals Of The Week: UCSF Catalyzes R&D Tech-Transfer Deals With Private Sector
Neither MedImmune, the biologics arm of AstraZeneca, nor the University of California, San Francisco, is a stranger to R&D collaboration between private industry and academia, but the agreement...
View ArticleClik here to view.
Financings of the Fortnight And the Neverending Venture Round
Somewhere out there, perhaps, is the end of NovImmune's Series B round.More than a year ago, our friends at START-UP examined the fates of biotechs that had reeled in huge private financing rounds....
View ArticleClik here to view.
Deals Of The Week: Novartis Places Bid To Dominate In Cancer
While the largest deal of the week, and certainly the one receiving the most attention, has been Actavis' expansion of its branded portfolio via its $25 billion purchase of Forest Laboratories, the...
View Article
